Epeius Pharma

Epeius Pharma is a cell and gene therapy company developing biological vehicles for the delivery of therapeutic proteins into the central nervous system. Epeius Pharma's platform could allow for an effective and scalable strategy for disease medication in neurodevelopmental and neurological pathologies that could benefit from direct neuron protein replacement treatments. Its first target indication will be Rett syndrome. Epeius Pharma was founded based on the joint research efforts of Professor Oded Rechavi and Shahar Bracha of the Department of Neurobiology, Wise Faculty of Life Sciences & Sagol School of Neuroscience, Tel Aviv University, and Dr. Lilach Sheiner, senior lecturer and research fellow at the Wellcome Center of Integrative Parasitology, University of Glasgow. It was licensed from Ramot, the technology transfer company of Tel Aviv University and Glasgow University.

Epeius Pharma has raised $3.5M in total funding across 1 rounds. The company is currently at the Seed stage. Key investors include RMGP Biopharma Investment Fund, FutuRx.

Epeius Pharma was founded in 2019 by Prof. Oded Rechavi (Co-Inventor), Shahar Bracha (Scientific Advisor & Co-inventor).

Epeius Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, with core technologies in Biologicals, Genes, Cells. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Epeius Pharma is based in Ilan Ramon Street 2, Ness Ziona, Israel.